表紙
市場調查報告書

Frost Radar:心房纖維顫動(AFib)醫療設備市場 - 2020年

Frost Radar: Medical Devices in Atrial Fibrillation Market, 2020

出版商 Frost & Sullivan 商品編碼 954119
出版日期 內容資訊 英文 53 Pages
商品交期: 最快1-2個工作天內
價格
Frost Radar:心房纖維顫動(AFib)醫療設備市場 - 2020年 Frost Radar: Medical Devices in Atrial Fibrillation Market, 2020
出版日期: 2020年08月05日內容資訊: 英文 53 Pages
簡介

本報告提供心房纖維顫動(AFib)形勢的新興趨勢相關分析,創新的解決方案,主要的市場區隔維持龍頭的主要企業相關資料、簡介。

AFib,是引起中風的血栓的最大原因,罹患致命性中風症的可能性高5倍。AFib的盛行率預計一般人口的約3%,今後30年成為2倍。預計為診斷及治療AFib的醫療設備的市場規模,2025年達到約150億美元。

目錄

策略性必要事項與成長環境

  • 策略性必要事項
  • 成長環境

Frost Radar

  • Frost Radar:心房纖維顫動醫療設備市場
  • Frost Radar:競爭環境

C2A (主要企業)

  • Abbott Laboratories
  • AliveCor
  • AtriCure
  • Baylis Medical
  • Biosense Webster (Johnson & Johnson)
  • Biotronik
  • Boston Scientific
  • Cardiofocus
  • Eko Health
  • Firstbeat Technologies
  • iRhythm Technologies
  • Japan Lifeline
  • Medtronic
  • Microlife AG
  • Microport Scientific
  • MyDiagnostick Medical (Applied Biomedical Systems)
  • Occlutech
  • Omron
  • Osypka AG
  • Philips
  • Stereotaxis
  • Vital Connect
  • Zenicor

策略性考察

  • 策略性考察

下一步:活用Frost Radar支援主要相關利益者

  • Frost Radar的重要性
  • Frost Radar支援CEO的成長團隊
  • Frost Radar支援投資者
  • Frost Radar支援客戶
  • Frost Radar支援董事會

Frost Radar分析

  • Frost Radar:未來的成長可能性基準
  • 免責聲明
目錄
Product Code: K4BB-54

Benchmarking Future Growth Potential

This Frost Radar™ analyzes emerging trends in the atrial fibrillation (AFib) landscape and profiles key market participants that deliver innovative solutions and maintain leadership in major segments in the care continuum, such as screening and monitoring, image-guided navigation and cardiac mapping, cardiac ablation, and left atrial appendage (LAA) occlusion.

AFib is the top cause of blood clots that lead to stroke, and persons with the condition are five times more likely to suffer a fatal stroke. The prevalence of AFib is about 3% of the general population and is expected to double over the next 30 years. The estimated market size of medical devices to diagnose and treat AFib is expected to reach about $15 billion in 2025. Abbot, Biosense Webster (J&J), Boston Scientific, and Medtronic lead the market for minimally invasive intervention for diagnosis and surgical treatment by offering a plethora of electrophysiological diagnostic and interventional devices. However, the market for screening and monitoring is witnessing the emergence of disruptive start-ups building clinical-grade personal ECG devices with superior specificity and sensitivity parameters. The increase in the number of catheter-based procedures and the introduction of technologically advanced cardiac ablation devices are expected to drive growth for EP ablation segment. Novel catheter-based technologies, such as contact force sensing, pulsated field ablation (PFA) and titratable laser energy are expected to gain more adoption in cardiac ablation procedures. Advanced 3D cardiac mapping and robotic navigation systems from Philips and Stereotaxis are making ablation procedures quicker and efficient. There is increasing collaboration between companies specializing in ablation segment and those specializing in cardiac mapping and navigations. Similarly, established device companies are likely to create synergistic partnerships with or strategically acquire emerging start-ups in the screening segment to keep pace with technological advancement and create a pipeline of cutting-edge products. The screening segment is expected to show higher growth in the care continuum due to greater emphasis on early detection and remote monitoring through clinically validated handheld devices and patches. Companies, such as AliveCor and iRhythm Technologies, have disrupted the screening and monitoring of heart rate variability (HRV) by making more compact and user-friendly devices, in addition to building robust data analytics for an accurate diagnosis.

The Frost Radar™ reveals the market positioning of companies in an industry using their growth and innovation scores as highlighted in the Frost Radar™ methodology. The document presents the competitive profiles of each of the companies and provides insight into their innovation capabilities, growth potential, and future roadmap. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned. Industry leaders on both the growth and innovation indices are recognized as best practice recipients.

Table of Contents

Strategic Imperative and Growth Environment

  • Strategic Imperative
  • Strategic Imperative (continued)
  • Growth Environment
  • Growth Environment (continued)
  • Growth Environment (continued)
  • Growth Environment (continued)

Frost Radar™

  • Frost Radar™: Medical Devices in Atrial Fibrillation Market
  • Frost Radar™: Competitive Environment
  • Frost Radar™: Competitive Environment (continued)

Companies to Action

  • Abbott Laboratories
  • AliveCor®
  • AtriCure
  • Baylis Medical
  • Biosense Webster (Johnson & Johnson)
  • Biotronik
  • Boston Scientific
  • Cardiofocus
  • Eko Health
  • Firstbeat Technologies
  • iRhythm Technologies
  • Japan Lifeline
  • Medtronic
  • Microlife AG
  • Microport Scientific
  • MyDiagnostick Medical (Applied Biomedical Systems)
  • Occlutech
  • Omron
  • Osypka AG
  • Philips
  • Stereotaxis
  • Vital Connect
  • Zenicor

Strategic Insights

  • Strategic Insights

Next Steps: Leveraging the Frost Radar™ to Empower Key Stakeholders

  • Significance of Being on the Frost Radar™
  • Frost Radar™ Empowers the CEO's Growth Team
  • Frost Radar™ Empowers Investors
  • Frost Radar™ Empowers Customers
  • Frost Radar™ Empowers the Board of Directors

Frost Radar™Analytics

  • Frost Radar™: Benchmarking Future Growth Potential
  • Frost Radar™: Benchmarking Future Growth Potential
  • Frost Radar™: Benchmarking Future Growth Potential
  • Legal Disclaimer